Literature DB >> 28741497

MYC: A Stratification Marker for Pancreatic Cancer Therapy.

Matthias Wirth1, Günter Schneider2.   

Abstract

One approach to improve cancer treatment is to stratify patients and to develop subgroup-specific therapies. We will discuss the potential of MYC as a stratification marker in pancreatic ductal adenocarcinoma. Furthermore, we will point to possibilities for how to annotate the MYC status and how to target MYC-associated vulnerabilities.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MYC; pancreatic cancer

Year:  2015        PMID： 28741497     DOI： 10.1016/j.trecan.2015.12.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  8 in total

1.  Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Authors:  Felix Orben; Katharina Lankes; Christian Schneeweis; Zonera Hassan; Hannah Jakubowsky; Lukas Krauß; Fabio Boniolo; Carolin Schneider; Arlett Schäfer; Janine Murr; Christoph Schlag; Bo Kong; Rupert Öllinger; Chengdong Wang; Georg Beyer; Ujjwal M Mahajan; Yonggan Xue; Julia Mayerle; Roland M Schmid; Bernhard Kuster; Roland Rad; Christian J Braun; Matthias Wirth; Maximilian Reichert; Dieter Saur; Günter Schneider
Journal:  JCI Insight       Date:  2022-05-23

2.  Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.

Authors:  Benjamin Bian; Martin Bigonnet; Odile Gayet; Celine Loncle; Aurélie Maignan; Marine Gilabert; Vincent Moutardier; Stephane Garcia; Olivier Turrini; Jean-Robert Delpero; Marc Giovannini; Philippe Grandval; Mohamed Gasmi; Mehdi Ouaissi; Veronique Secq; Flora Poizat; Rémy Nicolle; Yuna Blum; Laetitia Marisa; Marion Rubis; Jean-Luc Raoul; James E Bradner; Jun Qi; Gwen Lomberk; Raul Urrutia; Andres Saul; Nelson Dusetti; Juan Iovanna
Journal:  EMBO Mol Med       Date:  2017-04       Impact factor: 12.137

3.  SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.

Authors:  Alexander Biederstädt; Zonera Hassan; Christian Schneeweis; Markus Schick; Lara Schneider; Alexander Muckenhuber; Yingfen Hong; Gerrit Siegers; Lisa Nilsson; Matthias Wirth; Zahra Dantes; Katja Steiger; Kathrin Schunck; Steve Langston; H-P Lenhof; Andrea Coluccio; Felix Orben; Jolanta Slawska; Anna Scherger; Dieter Saur; Stefan Müller; Roland Rad; Wilko Weichert; Jonas Nilsson; Maximilian Reichert; Günter Schneider; Ulrich Keller
Journal:  Gut       Date:  2020-01-30       Impact factor: 23.059

4.  Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.

Authors:  Yu Pan; Qinglin Fei; Ping Xiong; Jianyang Yang; Zheyang Zhang; Xianchao Lin; Minggui Pan; Fengchun Lu; Heguang Huang
Journal:  Oncoimmunology       Date:  2019-03-01       Impact factor: 8.110

Review 5.  The SUMO pathway in pancreatic cancer: insights and inhibition.

Authors:  Christian Schneeweis; Zonera Hassan; Markus Schick; Ulrich Keller; Günter Schneider
Journal:  Br J Cancer       Date:  2020-10-19       Impact factor: 7.640

Review 6.  Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer.

Authors:  Yuan Cai; Kewa Gao; Bi Peng; Zhijie Xu; Jinwu Peng; Juanni Li; Xi Chen; Shuangshuang Zeng; Kuan Hu; Yuanliang Yan
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

7.  Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.

Authors:  Katharina Lankes; Zonera Hassan; María Josefina Doffo; Christian Schneeweis; Svenja Lier; Rupert Öllinger; Roland Rad; Oliver H Krämer; Ulrich Keller; Dieter Saur; Maximilian Reichert; Günter Schneider; Matthias Wirth
Journal:  Mol Oncol       Date:  2020-11-08       Impact factor: 6.603

8.  Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Nathiya Muthalagu; Tiziana Monteverde; Ximena Raffo-Iraolagoitia; Robert Wiesheu; Declan Whyte; Ann Hedley; Sarah Laing; Björn Kruspig; Rosanna Upstill-Goddard; Robin Shaw; Sarah Neidler; Curtis Rink; Saadia A Karim; Katarina Gyuraszova; Colin Nixon; William Clark; Andrew V Biankin; Leo M Carlin; Seth B Coffelt; Owen J Sansom; Jennifer P Morton; Daniel J Murphy
Journal:  Cancer Discov       Date:  2020-03-21       Impact factor: 39.397
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.